Genes associated with recessive phenotypes - considerations for testing and reporting

MUTYH

Compared to other recessive disorders, MUTYH-associated Polyposis is unusual in that: 

  1. The phenotype is adult-onset
  2. Cancer risk is high without intervention
  3. Carrier frequency is such that heterozygous variants in MUTYH may be frequently picked up incidentally (e.g. pan-cancer predisposition panels) 

For reproductive partner testing, we propose that:

Testing of reproductive partner(s) of a carrier of a MUTYH variant(s) is not typically recommended unless:
    • 1. The couple is consanguineous OR
    • 2. The partner is of Gujarati heritage
  • AND
    • 3. The result would influence family planning/reproductive decision-making AND/OR
    • 4. The result would inform clinical management and/or surveillance for their children

Regarding extent of testing, we propose:

  • Where partner testing is indicated for individuals in consanguineous relationships, targeted testing for the familial variant should be offered.
  • Where partner testing is indicated for individuals of Gujarati heritage, targeted testing for the recurrent variant c.1438G>T (p.Glu480Ter) should be offered.
  • Eligibility for broader testing (full sequencing of MUTYH and other relevant cancer/polyposis predisposition) should be considered for partners with a relevant personal/family phenotype.

Further information is available in the statement and manuscripts here below and here. 

MBD4

The identification of germline pathogenic variants in MBD4 presents challenges for variant reporting, genetic counselling and clinical management, particularly given the differing implications of heterozygous and biallelic variants. Biallelic pathogenic variants are associated with MBD4-associated neoplasia syndrome, whereas current evidence does not support a clinically actionable increase in cancer risk for heterozygous carriers.

This UKCGG statement provides pragmatic recommendations to support consistent reporting and management of germline MBD4 variants. It addresses the clinical implications of heterozygous and biallelic findings, considerations around reproductive partner testing, and the importance of appropriate interpretation in the context of the individual's phenotype and family history.

The statement aims to promote consistency across clinical and laboratory practice, while recognising the limitations of the current evidence and the need to review recommendations as further data emerge.

Loading...